Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein- mediated drug efflux activity

General Physiology and Biophysics

Volumn 28, Issue 4, 2009, Pages 391-403

  Gibalová, Lenka ^a   Sedlák, Ján ^b   Labudová, Martina ^c   Barančík, Miroslav ^a,d   Reháková, Alena ^a   Breier, Albert ^a   Sulová, Zdena ^a  

^a INSTITUTE OF MOLECULAR PHYSIOLOGY AND GENETICS   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c INSTITUTE OF VIROLOGY   (Slovakia)

^d INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Bax protein; Bcl 2 protein; Cisplatin induced apoptosis; Cytochrome c release; L1210; P gp mediated MDR

Indexed keywords

CISPLATIN; CYTOCHROME C; GLYCOPROTEIN P; LIPOCORTIN 5; MULTIDRUG RESISTANCE PROTEIN; OLIGOMER; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; VERAPAMIL; VINCRISTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOSOL; CYTOTOXICITY; DNA FRAGMENTATION; DRUG MECHANISM; LEUKEMIA L 1210; MITOCHONDRION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CISPLATIN; CYTOCHROMES C; CYTOPLASM; DNA FRAGMENTATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; MICE; NECROSIS; P-GLYCOPROTEIN; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; VINCRISTINE;

EID: 77349097774     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: 10.4149/pb_2009_04_391     Document Type: Article

References (47)

1. Barancik M., Polekova L., Mrazova T., Breier A., Stankovicova T., Slezak J. (1994): Reversal effects of several Ca(2+)-entry blockers, neuroleptics and local anaesthetics on P-glycoprotein-mediated vincristine resistance of L1210/VCR mouse leukaemic cell line. Drugs. Exp. Clin. Res. 20, 13-18
2. Barancik M., Bohacova V., Kvackajova J., Hudecova S., Krizanova O., Breier A. (2001): SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 14, 29-36; doi:10.1016/S0928-0987(01)00139-7
3. Barancik M., Bohacova V., Sedlak J., Sulova Z., Breier A. (2006): LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 29, 426-434; doi:10.1016/j.ejps.2006.08.006
4. Bohacova V., Kvackajova J., Barancik M., Drobna Z., Breier A. (2000): Glutathione S-transferase does not play a role in multidrug resistance of L1210/VCR cell line. Physiol. Res. 49, 447-453
5. Bohacova V., Sulova Z., Dovinova I., Polakova E., Barancik M., Uhrik B., Orlicky J., Breier A. (2006): L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoprotein. Toxicol. In Vitro 20, 1560-1568; doi:10.1016/j.tiv.2006.07.011
6. Breier A., Drobna Z., Docolomansky P., Barancik M. (2000): Cytotoxic activity of several unrelated drugs on L1210 mouse leukemic cell sublines with P-glycoprotein (PGP) mediated multidrug resistance (MDR) phenotype. A QSAR study. Neoplasma 47, 100-106
7. Breier A., Barancik M., Sulova Z., Uhrik B. (2005): P-glycoprotein-- implications of metabolism of neoplastic cells and cancer therapy. Curr. Cancer Drug Targets 5, 457-468; doi:10.2174/1568009054863636
8. Brunelle J. K., Letai A. (2009): Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell. Sci. 122, 437-441; doi:10.1242/jcs.031682
9. Campos L., Oriol P., Sabido O., Guyotat D. (1997): Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells. Leuk. Lymphoma 27, 119-125
10. Chao C. C. (1996): Cross-resistance to cis-diamminedichloro platinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair. Eur. J. Pharmacol. 305, 213-222; doi:10.1016/0014-2999(96)00168-9
11. Cho H. J., Kim J. K., Kim K. D., Yoon H. K., Cho M. Y., Park Y. P., Jeon J. H., Lee E. S., Byun S. S., Lim H. M., Song E. Y., Lim J. S., Yoon D. Y., Lee H. G., Choe Y. K. (2006): Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett. 237, 56-66; doi:10.1016/j.canlet.2005.05.039
12. Cipak L., Rauko P., Miadokova E., Cipakova I., Novotny L. (2003): Effects of flavonoids on cisplatin-induced apoptosis of HL-60 and L1210 leukemia cells. Leuk. Res. 27, 65-72; doi:10.1016/S0145-2126(02)00063-2
13. Dave Z., Byfield M., Bossy-Wetzel E. (2008): Assessing mitochondrial outer membrane permeabilization during apoptosis. Methods 46, 319-323; doi:10.1016/j.ymeth.2008.10.019
14. Degli Esposti M., Dive C. (2003): Mitochondrial membrane permeabilisation by Bax/Bak. Biochem. Biophys. Res. Commun. 304, 455-461; doi:10.1016/S0006-291X(03)00617-X
15. Del Principe M. I., Del Poeta G., Maurillo L., Buccisano F., Venditti A., Tamburini A., Bruno A., Cox M. C., Suppo G., Tendas A., Gianni L., Postorino M., Masi M., Del Principe D., Amadori S. (2003): P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. Br. J. Haematol. 121, 730-738; doi:10.1046/j.1365-2141.2003.04343.x
16. Fiala R., Sulová Z., El-Saggan A. H., Uhrík B., Liptaj T., Dovinová I., Hanušovská E., Drobná Z., Barančík M., Breier A. (2003): P-glycoprotein-mediated multidrug resistance phenotype of L1210/VCR cells is associated with decreases of oligoand/or polysaccharide contents. Biochim. Biophys. Acta 1639, 213-224
17. Gerlier D., Thomasset N. (1986): Use of MTT colorimetric assay to measure cell activation. J. Immunol. Methods 94, 57-63; doi:10.1016/0022- 1759(86)90215-2
18. Gonzalez V. M., Fuertes M. A., Alonso C., Perez J. M. (2001): Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59, 657-663
19. Gross A., Jockei J., Wei M. C., Korsmeyer S. J. (1998): Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 17, 3878-3885; doi:10.1093/emboj/17.14.3878
20. Hockenbery D. M., Zutter M., Hickey W., Nahm M., Korsmeyer S. J. (1991): BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. U. S. A. 88, 6961-6965; doi:10.1073/pnas.88.16.6961
21. Kišucká J., Barančík M., Boháč ová V., Breier A. (2001): Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen. Physiol. Biophys. 20, 439-444
22. Krishan A., Dandekar P. D. (2005): DAPI fluorescence in nuclei isolated from tumors. J. Histochem. Cytochem. 53, 1033-1036; doi:10.1369/jhc. 4B6563.2005
23. Kupsáková I., Rybár A., Dočolomanský P., Drobná Z., Stein U., Walther W., Barančík M., Breier A. (2004): Reversal of P-glycoprotein mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline. A QSAR study. Eur. J. Pharm. Sci. 21, 283-293; doi:10.1016/j.ejps.2003.10.019
24. Laane E., Panaretakis T., Pokrovskaja K., Buentke E., Corcoran M., Soderhall S., Heyman M., Mazur J., Zhivotovsky B., Porwit A., Grander D. (2007): Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Haematologica 92, 1460-1469; doi:10.3324/haematol.10543
25. Laemmli U. K. (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685; doi:10.1038/227680a0
26. Lessene G., Czabotar P. E., Colman P. M. (2008): BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug. Discov. 7, 989-1000; doi:10.1038/nrd2658
27. Liu X., Li P., Widlak P., Zou H., Luo X., Garrard W. T., Wang X. (1998): The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc. Nad. Acad. Sci. U. S. A. 95, 8461-8466; doi:10.1073/pnas.95.15.8461
28. Marschitz I., Tinhofer I., Hittmair A., Egle A., Kos M., Greil R. (2000): Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. Am. J. Clin. Pathol. 113, 219-229; doi:10.1309/491W-L1TN-UFQX-T61B
29. Oltvai Z. N., Milliman C. L., Korsmeyer S. J. (1993): Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619; doi:10.1016/0092-8674(93)90509-O
30. Orlický J., Sulová Z., Dovinová I., Fiala R., Záhradniková A. Jr., Breier A. (2004): Functional fluo-3/AM assay on P-glycoprotein transport activity in L1210/VCR cells by confocal microscopy. Gen. Physiol. Biophys. 23, 357-366
31. Pauwels E. K., Erba P., Mariani G., Gomes C. M. (2007): Multidrug resistance in cancer: its mechanism and its modulation. Drug News Perspect. 20, 371-377; doi:10.1358/dnp.2007.20.6.1141496
32. Poleková L., Barančík M., Mrázová T., Pirker R., Wallner J., Sulová Z., Breier A. (1992): Adaptation of mouse leukemia cells L1210 to vincristine. Evidence for expression of P-glycoprotein. Neoplasma 39, 73-77
33. Pop I., Pop L., Vitetta E. S., Ghetie M. A. (2008): Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein. Oncol. Rep. 19, 889-895
34. Ren L., Xiao L., Hu J. (2007): MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. 27, 721-724
35. Šereš M., Poláková E., Križ anová O., Hudecová S., Klymenko S. V., Breier A., Sulová Z. (2008): Overexpression of P-glycoprotein in L1210/VCR cells is associated with changes in several endoplasmic reticulum proteins that may be partially responsible for the lack of thapsigargin sensitivity. Gen. Physiol. Biophys. 27, 211-221
36. Sorenson C. M., Barry M. A., Eastman A. (1990): Analysis of events associated with cell cycle arrest at g2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. 82, 749-755; doi:10.1093/jnci/82.9.749
37. Sulová Z., Orlický J., Fiala R., Dovinová I., Uhrík B., Šereš M., Gibalová L., Breier A. (2005): Expression of P-glycoprotein in L1210 cells is linked with rise in sensitivity to Ca2+. Biochem. Biophys. Res. Commun. 335, 777-784; doi:10.1016/j.bbrc.2005.07.144
38. Sulová Z., Macejová D., Šereš M., Sedlák J., Brtko J., Breier A. (2008): Combined treatment of P-gp positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicol. In Vitro 22, 96-105; doi:10.1016/j.tiv.2007.08.011
39. Sulová Z., Mislovičová D., Gibalová L., Vajčnerová Z., Poláková E., Uhrík B., Tylková L., Kovárová A., Sedlák J., Breier A. (2009): Vincristine-induced overexpression of P-glycoprotein in L1210 cells is associated with remodeling of cell surface saccharides. J. Proteome Res. 8, 513-520; doi:10.1021/pr8007094
40. Tabe Y., Konopleva M., Contractor R., Munsell M., Schober W. D., Jin L., Tsutsumi-Ishii Y., Nagaoka I., Igari J., Andreeff M. (2006): Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107, 1546-1554; doi:10.1182/blood-2004-10-4126
41. Takara K., Sakaeda T., Tanigawara Y., Nishiguchi K., Ohmoto N., Horinouchi M., Komada F., Ohnishi N., Yokoyama T., Okumura K. (2002): Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur. J. Pharm. Sci. 16, 159-165; doi:10.1016/S0928- 0987(02)00082-9
42. Takara K., Tsujimoto M., Kokufu M., Ohnishi N., Yokoyama T. (2003): Up-regulation of MDR1 function and expression by cisplatin in LLC-PK1 cells. Biol. Pharm. Bull. 26, 205-9; doi:10.1248/bpb.26.205
43. Towbin H., Staehelin T., Gordon J. (1979): Electrophoretic transfer of proteins from Polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 76, 4350-4354; doi:10.1073/pnas.76.9.4350
44. Tsai S. Y., Sun N. K., Lu H. P., Cheng M. L., Chao C. C. (2007): Involvement of reactive oxygen species in multidrug resistance of a vincristine-selected lymphoblastoma. Cancer Sci. 98, 1206-1214; doi:10.1111/j.1349-7006.2007.00513.x
45. Yan X. D., Li M., Yuan Y., Mao N., Pan L. Y. (2007): Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncol. Rep. 17, 1163-1169
46. Yang X., Page M. (1995): P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol. Res. 7, 619-624
47. Zhou S. F. (2008): Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38, 802-832; doi:10.1080/00498250701867889